 |
PDBsum entry 5jdb
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
5jdb
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Viral protein
|
|
|
Title:
|
|
Binding specificity of p[8] vp8 Proteins of rotavirus vaccine strains with histo-blood group antigens
|
|
Structure:
|
|
Outer capsid protein vp4. Chain: a, b, c, d, e, f. Fragment: unp residues 64-223. Engineered: yes
|
|
Source:
|
|
Rotavirus a. Organism_taxid: 28875. Expressed in: escherichia coli k-12. Expression_system_taxid: 83333.
|
|
Resolution:
|
|
|
1.90Å
|
R-factor:
|
0.204
|
R-free:
|
0.230
|
|
|
Authors:
|
|
X.Sun,N.Guo,D.Li,Y.Zhou,M.Jin,G.Xie,L.Pang,Q.Zhang,Y.Cao,Z.Duan
|
|
Key ref:
|
|
X.Sun
et al.
(2016).
Binding specificity of P[8] VP8* proteins of rotavirus vaccine strains with histo-blood group antigens.
Virology,
495,
129-135.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
16-Apr-16
|
Release date:
|
13-Jul-16
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
E2EA82
(E2EA82_9VIRU) -
Outer capsid protein VP4 from Rotavirus A
|
|
|
|
Seq:
Struc:
|
|
|
|
775 a.a.
160 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Virology
495:129-135
(2016)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Binding specificity of P[8] VP8* proteins of rotavirus vaccine strains with histo-blood group antigens.
|
|
X.Sun,
N.Guo,
D.Li,
M.Jin,
Y.Zhou,
G.Xie,
L.Pang,
Q.Zhang,
Y.Cao,
Z.J.Duan.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
RotaTeq(®) and Rotarix™ are two common human rotavirus (RV) vaccines
currently on the market worldwide. Recent studies indicate histo-blood group
antigens (HBGAs) may be attachment factors for RVs. The P[8] VP8* proteins of
RotaTeq and Rotarix were expressed and purified, and their binding specificities
were evaluated. Saliva-based binding assays showed that the VP8* proteins bound
to the saliva samples of secretors irrespective of ABO blood types. However, in
the oligosaccharide binding assay, the VP8* proteins displayed no specific
binding to the HBGAs tested, including Lewis b and H1. The structure of RotaTeq
P[8] VP8* was solved at 1.9Å. Structural comparisons revealed that the putative
receptor binding site was different to that of other genotypes and displayed a
novel potential binding region. These findings indicate RotaTeq and Rotarix may
have better efficiency in areas with a high percentage of secretors.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
